Womble Bond Dickinson has advised Camden Partners Nexus, a Baltimore-based venture capital firm with a focus on biomedical technology companies, on its participation in an $80m series B investment round in COMPASS Pathways.

COMPASS Pathways, a London-based mental health organization, will use the funding to expand on its lead program in psilocybin therapy for treatment-resistant depression. It will also support further research and advance the company's preclinical pipeline, develop digital technologies and help establish new academic and clinical research partnerships.

The transaction was led by WBD's corporate teams in the UK and US including London-based partner Leon Miller and Baltimore-based partner Newt Fowler and associate Brian Meltzer.

Leon Miller, partner, commented:

"It was a pleasure working with our US colleagues to advise Camden Partners Nexus on this Series B investment. Our strong credentials in venture capital coupled with our unique transatlantic offering enabled us to provide the best possible outcome for our client."